Comment on published article “A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale”

Geahča maid

• A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale
  Dahkki: Kabir Sardana, et al.
  Almmustuhtton: (2025-05-01)
• Comment on published article “A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale”
  Dahkki: Ankan Gupta, et al.
  Almmustuhtton: (2026-03-01)
• Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
  Dahkki: Kabir Sardana, et al.
  Almmustuhtton: (2023-01-01)
• Efficacy and Safety of Low-Dose Methotrexate in Generalized and Recalcitrant Lichen Planus: A Retrospective Study at a Tertiary Care Center
  Dahkki: Ananta Khurana, et al.
  Almmustuhtton: (2024-10-01)
• Therapeutic updates on the management of tinea corporis or cruris in the era of Trichophyton Indotineae: Separating evidence from hype—A narrative review
  Dahkki: Ananta Khurana, et al.
  Almmustuhtton: (2023-01-01)